SR
SRZN.US Surrozen Inc
- Market cap
- USD 616M
- P/E
- -
- P/B
- 2.50x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SRZN.US undervalued?
Graham numberThe Graham number of Surrozen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Surrozen Inc fundamental analysis
No fundamental analysis for Surrozen Inc yet.
Surrozen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor …
Full company profileSurrozen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Surrozen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 12.5M | 12.5M | 10.7M | 3.48M | 173K |
| Gross Profit | - | -2.93M | -3.30M | 12.5M | -27.2M | 10.7M | 2.94M | 0.00 |
| Operating Income | -25.1M | -32.8M | -54.4M | -44.3M | -45.8M | -25.5M | -42.1M | -51.3M |
| EBITDA | -22.8M | -32.4M | -52.3M | -42.4M | -41.1M | -62.1M | -241M | -275M |
| Net Income | -24.4M | -32.6M | -52.5M | -27.7M | -43.0M | -63.6M | -242M | -276M |
| EPS | -62 | -41 | -22 | -12 | -21 | -22 | -32 | -23 |
| Balance Sheet | ||||||||
| Total Assets | 42.5M | 62.1M | 137M | 89.4M | 46.1M | 48.5M | 98.7M | 109M |
| Total Liabilities | 13.1M | 14.8M | 27.5M | 13.4M | 8.15M | 69.8M | 286M | 445M |
| Shareholders' Equity | 29.4M | 47.3M | 110M | 76.0M | 37.9M | -21.4M | -188M | -336M |
| Cash & Short-term Investments | 29.1M | 49.2M | 102M | 75.8M | 36.0M | 34.6M | 89.2M | 100M |
| Total Debt | 10.7M | 9.60M | 7.79M | 5.60M | 3.38M | 8.47M | 6.64M | 5.84M |
| Cash Flow | ||||||||
| Operating Cash Flow | -21.1M | -29.1M | -48.8M | -44.1M | -40.4M | -17.6M | -30.2M | -33.0M |
| Capital Expenditure | 1.56M | 874K | 1.27M | 728K | 398K | 26.0K | 128K | 221K |
| Free Cash Flow | -22.6M | -30.0M | -50.1M | -44.9M | -40.8M | -17.7M | -30.4M | -33.2M |
| Ratios | ||||||||
| ROE | -82.9% | -69.0% | -47.9% | -36.4% | -113.5% | - | - | - |
| ROA | -57.3% | -52.6% | -38.3% | -30.9% | -93.4% | -131.1% | -245.1% | -253.2% |
| Net Profit Margin | - | - | - | -221.4% | -344.3% | -596.6% | -6,960.8% | -159,270.8% |
| Debt to Equity | 0.36x | 0.20x | 0.07x | 0.07x | 0.09x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Surrozen Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 48.4M | 61 | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Dec 14, 2023.
Who owns Surrozen Inc
- Insiders 1.93%
- Institutions 88.08%
- Public & others 9.99%
- Shares outstanding 19.1M
- Free float 12.4M
Top funds holding SRZN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 282K | 1.59% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 186K | 1.05% | 0.00% | Oct 2026 |
| Janus Henderson Small/Md Cp Gr Alpha ETF | 169K | 0.95% | 0.00% | Oct 2026 |
| MEDICAL BioHealth EUR Acc | 129K | 0.73% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 84.9K | 0.48% | +5.79% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 69.8K | 0.39% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 43.3K | 0.24% | +2.18% | Sep 2026 |
| Fidelity Extended Market Index | 36.9K | 0.21% | -13.39% | Sep 2026 |
| iShares Micro-Cap ETF | 22.2K | 0.13% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 18.0K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 16.2K | 0.09% | -0.06% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 13.7K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 13.7K | 0.08% | 0.00% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 13.0K | 0.07% | 0.00% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 9.78K | 0.06% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 Growth ETF | 7.97K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding SRZN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 1.47M | 8.29% | 0.00% | Jun 2026 |
| Boxer Capital Management, LLC | 1.11M | 6.22% | +44.29% | Jun 2026 |
| Kalehua Capital Management LLC | 770K | 4.34% | 0.00% | Jun 2026 |
| Millennium Management LLC | 683K | 3.84% | -6.57% | Jun 2026 |
| Point72 Asset Management, L.P. | 664K | 3.74% | 0.00% | Jun 2026 |
| VR Adviser, LLC | 633K | 3.56% | 0.00% | Jun 2026 |
| StemPoint Capital LP | 603K | 3.39% | -16.47% | Jun 2026 |
| Perceptive Advisors LLC | 504K | 2.84% | +119.70% | Jun 2026 |
| Spruce Street Capital LP | 432K | 2.43% | 0.00% | Jun 2026 |
| BlackRock Inc | 395K | 2.22% | +1,317.77% | Jun 2026 |
| Vanguard Capital Management, LLC | 393K | 2.21% | +132.15% | Jun 2026 |
| BRAIDWELL LP | 391K | 2.20% | -1.35% | Jun 2026 |
| Vestal Point Capital LP | 305K | 1.71% | -10.02% | Jun 2026 |
| 5AM Venture Management, LLC | 271K | 1.53% | -30.00% | Jun 2026 |
| Vivo Capital, LLC | 260K | 1.46% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 205K | 1.15% | +0.56% | Jun 2026 |
| Geode Capital Management, LLC | 202K | 1.13% | +206.23% | Jun 2026 |
| Longwood Capital Partners LLC | 173K | 0.98% | +0.32% | Jun 2026 |
| Regents Of The University Of California | 133K | 0.75% | 0.00% | Jun 2026 |
| State Street Corp | 133K | 0.75% | +380.00% | Jun 2026 |
Surrozen Inc company profile
- Company name
- Surrozen Inc
- Ticker
- SRZN.US
- Exchange
- USA Stocks
- Listed since
- Jan 11, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Fiscal year end
- December
- Address
- 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 489 9000
- Website
- surrozen.com
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Surrozen Inc management
10- Mr. Craig C. Parker M.B.A.CEO, President & Director · born 1962
- Mr. Charles WilliamsCOO & Corporate Secretary · born 1980
- Dr. Yang Li Ph.D.Executive Vice President of Research · born 1969
- Dr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory Board
- Dr. Roeland Nusse Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1950
- Dr. Calvin Kuo M.D., Ph.D.Co-Founder & Member of Scientific Advisor
- Mr. Andrew MalekiChief Financial Officer · born 1990
- Dr. Daniel L. Chao M.D., Ph.D.VP & Head of Clinical Development
- Mr. Michael Lauw M.S.W.Senior Vice President of Development Operations
- Esther JhunController